Ovarian Neoplasms clinical trials

The registry lists 3,385 studies for Ovarian Neoplasms across more than 10 countries. 792 are recruiting or about to start. 1,881 of them are mainly about Ovarian Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 5 narrower conditions too, such as Carcinoma, Ovarian Epithelial: 3,844 studies, 867 open.

ClinicalTrials.gov finds 5,341 studies for Ovarian Neoplasms. How that becomes 3,379 here

This page counts the studies the registry files under Ovarian Neoplasms, and those it files under no condition that list Ovarian Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

5,341Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−443Filed under a narrower condition, counted on its own pageCarcinoma, Ovarian Epithelial 353 · Hereditary Breast and Ovarian Cancer Syndrome 44 · Carcinoma, Endometrioid 18 · Ovarian Germ Cell Cancer 6 · Brenner Tumor 5
−88List Ovarian Neoplasms as a condition, but the registry did not file them under itMost often written as “Stage III Ovarian Cancer AJCC v6 and v7” (9), “Stage IV Ovarian Cancer AJCC v6 and v7” (9), and “High Grade Serous Ovarian Cancer” (8). The registry filed them under other conditions only, most often Fallopian Tube Neoplasms (28) and Triple Negative Breast Neoplasms (13).
−1,431Match it another way93 name it in the title, 13 in a keyword, and 1,325 by a synonym or other text the search reads.
3,379The count on this page114 of them list Ovarian Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Ovarian Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,488
Recruiting: 604
Terminated: 392
Status unknown: 327
Active, not recruiting: 253
Not yet recruiting: 172

Phase

Phase 2: 1,244
Phase 1: 1,051
Phase 3: 274
Early Phase 1: 51
Phase 4: 33

Where

United States: 1,778
China: 392
United Kingdom: 292
France: 291
Canada: 272
Spain: 268

Who runs them

National Cancer Institute (NCI) (130) · Memorial Sloan Kettering Cancer Center (80) · M.D. Anderson Cancer Center (78) · Gynecologic Oncology Group (75) · AstraZeneca (66) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (40) · Dana-Farber Cancer Institute (36) · Eli Lilly and Company (29)

What is being tested here

Drugs under test in Ovarian Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Bevacizumab	19	19	99
Olaparib	13	17	63
Paclitaxel	12	28	151
Fluzoparib	12	3	21
Carboplatin	11	28	161
Niraparib	9	6	43
Cisplatin	7	9	51
Pembrolizumab	7	3	35
Cyclophosphamide	6	2	35
Apatinib	6	3	21

Drug classes tested here PARP inhibitors 43 open · Immune checkpoint inhibitors 25 open · Angiogenesis inhibitors 20 open · Tyrosine kinase inhibitors (TKIs) 18 open · Antimitotic agents 17 open

Coming up

100phase 3 studies under way

310studies finish main data collection within a year17 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Avelumab Program Rollover Study · Phase 3 · EMD Serono Research & Development Institute, Inc.
Dec 2026Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · Phase 3 · Genelux Corporation
Dec 2026Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery · Phase 3 · CanariaBio Inc.
Dec 2026JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer · Phase 3 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Dec 2026Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing · Phase 3 · Pfizer
Feb 2027Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · Phase 3 · NRG Oncology
Mar 2027HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer · Phase 3 · Hansoh BioMedical R&D Company
Apr 2027Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer · Phase 3 · AbbVie
Apr 2027Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib · Phase 3 · AstraZeneca
May 2027A Study of SHR-A1811 in Subjects With Ovarian Cancer · Phase 3 · Jiangsu HengRui Medicine Co., Ltd.

Who these studies take

Of the 604 Ovarian Neoplasms studies recruiting now, 441 (73%) set no upper age limit and 107 (18%) stop at 75 or younger. 39 (6%) take children under 18. 359 (59%) are for women only and 0 (0%) for men only; 45 (7%) take healthy volunteers.

Recruiting studies that take each age, of 604
Age	Women	Men
10	31 (5%)	14 (2%)
18	549 (91%)	231 (38%)
30	585 (97%)	240 (40%)
40	591 (98%)	241 (40%)
50	595 (99%)	241 (40%)
65	591 (98%)	241 (40%)
75	558 (92%)	231 (38%)
85	479 (79%)	211 (35%)

Across all 3,385 studies, recruiting or not: 13% stop at 75 or younger and 3% at 65; 8% take children; 66% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Ovarian Neoplasms studies take

Of 380 phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 50 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	50 mo32–76 · 380 studies	47 mo29–65 · 210 studies	54 mo35–82 · 170 studies
Phase 1/2	65 mo44–88 · 173 studies	61 mo44–88 · 116 studies	66 mo45–110 · 57 studies
Phase 2	47 mo33–72 · 344 studies	37 mo23–51 · 116 studies	54 mo40–80 · 228 studies
Phase 3	59 mo37–89 · 125 studies	45 mo34–72 · 73 studies	81 mo48–115 · 52 studies
Interventional, no phase	46 mo23–76 · 293 studies	—	46 mo23–76 · 282 studies
Observational	61 mo35–185 · 268 studies	53 mo35–71 · 52 studies	71 mo35–206 · 216 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out